drugset / Trial / NCT01533753

Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer

NCT01533753

Phase 2 Terminated 5 enrolled University of Wisconsin, Madison
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the change in quality of life over a 6 month period between gabapentin and venlafaxine in men with prostate cancer treated for hot flashes related to androgen deprivation therapy.

Timeline

Start
2012-02
Primary completion
2014-01
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Gabapentin Small molecule 300 mg Oral
Subject Venlafaxine Small molecule 37.5 mg Oral

Indications